2025-2026 Regular SessionIllinois Legislature

SB2385: PATIENT ACCESS 340B PHARMACY

Legislative Summary

Creates the Patient Access to Pharmacy Protection Act. Defines terms. Provides that no person, including a pharmaceutical manufacturer, may deny, restrict, prohibit, condition, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B covered entity or a 340B contract pharmacy authorized to receive 340B drugs on behalf of the 340B covered entity unless such receipt is prohibited by federal law. Provides that no person, including a pharmaceutical manufacturer, may impose any restriction on the ability of a 340B covered entity to contract with or designate a 340B contract pharmacy including restrictions relating to the number, location, ownership, or type of 340B contract pharmacy. Provides that no person, including a pharmaceutical manufacturer, may require or compel a 340B covered entity or 340B contract pharmacy to submit or otherwise provide ingredient cost or pricing data pertinent to 340B drugs unless required by State or federal law; institute requirements in any way relating to how a 340B covered entity manages its inventory of 340B drugs that are not required by a State or federal agency, including requirements relating to the frequency or scope of audits of inventory management systems of a 340B covered entity or a 340B contract pharmacy; or submit data or information that is not required by State or federal law as a condition for a 340B covered entity, its 340B contract pharmacy, or a location otherwise authorized by a 340B covered entity to receive 340B drugs. Sets forth provisions concerning enforcement of this Act; preemption of this Act; and severability of this Act. Effective immediately.

Demographic Impact

Overall analysis of equity impact

70% Positive
Medium ConfidenceView detailed demographic breakdown ↓

Unlock Full Demographic Insights

Go beyond the overall score.

Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.

Enable full analysis features for your organization.

Contact Sales to Learn More

Or email us directly at sales@legiequity.us.

Bill History

2/7/2025
Filed with Secretary by Sen. David Koehler
Senate
2/7/2025
First Reading
Senate
2/7/2025
Referred to Assignments
Senate
2/14/2025
Added as Co-Sponsor Sen. Michael W. Halpin
Senate
2/20/2025
Added as Co-Sponsor Sen. Javier L. Cervantes
Senate
2/24/2025
Added as Co-Sponsor Sen. Graciela Guzmán
Senate
2/26/2025
Added as Co-Sponsor Sen. Napoleon Harris, III
Senate
2/27/2025
Added as Co-Sponsor Sen. Mike Porfirio
Senate
3/3/2025
Added as Co-Sponsor Sen. Paul Faraci
Senate
3/4/2025
Added as Co-Sponsor Sen. Celina Villanueva
Senate
3/5/2025
Added as Co-Sponsor Sen. Patrick J. Joyce
Senate
3/5/2025
Added as Co-Sponsor Sen. Lakesia Collins
Senate
3/5/2025
Added as Co-Sponsor Sen. Mary Edly-Allen
Senate
3/6/2025
Added as Co-Sponsor Sen. Kimberly A. Lightford
Senate
3/6/2025
Added as Co-Sponsor Sen. Rachel Ventura
Senate
3/6/2025
Added as Co-Sponsor Sen. Mike Simmons
Senate
3/6/2025
Added as Co-Sponsor Sen. Robert F. Martwick
Senate
3/7/2025
Added as Co-Sponsor Sen. Steve Stadelman
Senate
3/10/2025
Added as Chief Co-Sponsor Sen. Mattie Hunter
Senate
3/12/2025
Assigned to Executive
Senate
3/21/2025
Rule 2-10 Committee Deadline Established As April 4, 2025
Senate
4/1/2025
Added as Co-Sponsor Sen. Jil Tracy
Senate
4/3/2025
Added as Co-Sponsor Sen. Terri Bryant
Senate
4/4/2025
Added as Chief Co-Sponsor Sen. Dale Fowler
Senate
4/4/2025
Added as Co-Sponsor Sen. Ram Villivalam
Senate
4/4/2025
Rule 2-10 Committee Deadline Established As April 11, 2025
Senate
4/10/2025
Added as Co-Sponsor Sen. Laura M. Murphy
Senate
4/11/2025
Rule 2-10 Committee/3rd Reading Deadline Established As May 9, 2025
Senate